Founded by Luc Van Rompaey, a former executive at Galapagos and Argenx, Dualyx combines the expertise of Argenx with the research projects of VIB (Flanders’ strategic research center for biotechnology and life sciences) as well as three universities: UGent and KU Leuven in Flanders, and Universität Würzburg in Germany. This unique collaboration has resulted in a pioneering approach to activate regulatory T-cells, restoring balance in the immune system and reducing the exaggerated immune response that causes damage in autoimmune diseases. 

The impressive funding amount of EUR 40 million comes from a consortium of European investors led by Fountain Healthcare Partners, Forbion, and Andera Partners. This substantial investment, particularly for a company that is only three years old and still in the early stages of development, demonstrates the high level of confidence in both Dualyx’s team and technology. 

This success story further highlights the innovative capabilities of companies and organizations in Flanders’ life sciences & health industry. Dualyx joins the ranks of other successful spin-offs, including Agomab, which raised USD 140 million within 5 years of its inception. The strong foundation and collaboration between Flanders-based companies and research institutions foster an environment of scientific excellence and entrepreneurial spirit, driving breakthrough discoveries in the biotech field.